BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 30987970)

  • 1. Par-4 overexpression impedes leukemogenesis in the Eµ-TCL1 leukemia model through downregulation of NF-κB signaling.
    Greene JT; Mani R; Ramaswamy R; Frissora F; Yano M; Zapolnik K; Harrington B; Wasmuth R; Tran M; Mo X; McKenna M; Rangnekar VM; Byrd JC; Bondada S; Muthusamy N
    Blood Adv; 2019 Apr; 3(8):1255-1266. PubMed ID: 30987970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ROR1 can interact with TCL1 and enhance leukemogenesis in Eμ-TCL1 transgenic mice.
    Widhopf GF; Cui B; Ghia EM; Chen L; Messer K; Shen Z; Briggs SP; Croce CM; Kipps TJ
    Proc Natl Acad Sci U S A; 2014 Jan; 111(2):793-8. PubMed ID: 24379361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. miR-181b as a therapeutic agent for chronic lymphocytic leukemia in the Eµ-TCL1 mouse model.
    Bresin A; Callegari E; D'Abundo L; Cattani C; Bassi C; Zagatti B; Narducci MG; Caprini E; Pekarsky Y; Croce CM; Sabbioni S; Russo G; Negrini M
    Oncotarget; 2015 Aug; 6(23):19807-18. PubMed ID: 26090867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD5+CD23+ leukemic cell populations in TCL1 transgenic mice show significantly increased proliferation and Akt phosphorylation.
    Efanov A; Zanesi N; Nazaryan N; Santanam U; Palamarchuk A; Croce CM; Pekarsky Y
    Leukemia; 2010 May; 24(5):970-5. PubMed ID: 20357824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p66Shc deficiency in the Eμ-TCL1 mouse model of chronic lymphocytic leukemia enhances leukemogenesis by altering the chemokine receptor landscape.
    Patrussi L; Capitani N; Ulivieri C; Manganaro N; Granai M; Cattaneo F; Kabanova A; Mundo L; Gobessi S; Frezzato F; Visentin A; Finetti F; Pelicci PG; D'Elios MM; Trentin L; Semenzato G; Leoncini L; Efremov DG; Baldari CT
    Haematologica; 2019 Oct; 104(10):2040-2052. PubMed ID: 30819907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel role of prostate apoptosis response-4 tumor suppressor in B-cell chronic lymphocytic leukemia.
    McKenna MK; Noothi SK; Alhakeem SS; Oben KZ; Greene JT; Mani R; Perry KL; Collard JP; Rivas JR; Hildebrandt GC; Fleischman RA; Durbin EB; Byrd JC; Wang C; Muthusamy N; Rangnekar VM; Bondada S
    Blood; 2018 Jun; 131(26):2943-2954. PubMed ID: 29695515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression.
    Bichi R; Shinton SA; Martin ES; Koval A; Calin GA; Cesari R; Russo G; Hardy RR; Croce CM
    Proc Natl Acad Sci U S A; 2002 May; 99(10):6955-60. PubMed ID: 12011454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tcl1 interacts with Atm and enhances NF-κB activation in hematologic malignancies.
    Gaudio E; Spizzo R; Paduano F; Luo Z; Efanov A; Palamarchuk A; Leber AS; Kaou M; Zanesi N; Bottoni A; Costinean S; Rassenti LZ; Nakamura T; Kipps TJ; Aqeilan RI; Pekarsky Y; Trapasso F; Croce CM
    Blood; 2012 Jan; 119(1):180-7. PubMed ID: 22065599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longitudinal analyses of CLL in mice identify leukemia-related clonal changes including a Myc gain predicting poor outcome in patients.
    Öztürk S; Paul Y; Afzal S; Gil-Farina I; Jauch A; Bruch PM; Kalter V; Hanna B; Arseni L; Roessner PM; Schmidt M; Stilgenbauer S; Dietrich S; Lichter P; Zapatka M; Seiffert M
    Leukemia; 2022 Feb; 36(2):464-475. PubMed ID: 34417556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tcl1 functions as a transcriptional regulator and is directly involved in the pathogenesis of CLL.
    Pekarsky Y; Palamarchuk A; Maximov V; Efanov A; Nazaryan N; Santanam U; Rassenti L; Kipps T; Croce CM
    Proc Natl Acad Sci U S A; 2008 Dec; 105(50):19643-8. PubMed ID: 19064921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of rapamycin on mouse chronic lymphocytic leukemia and the development of nonhematopoietic malignancies in Emu-TCL1 transgenic mice.
    Zanesi N; Aqeilan R; Drusco A; Kaou M; Sevignani C; Costinean S; Bortesi L; La Rocca G; Koldovsky P; Volinia S; Mancini R; Calin G; Scott CP; Pekarsky Y; Croce CM
    Cancer Res; 2006 Jan; 66(2):915-20. PubMed ID: 16424025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Absence of caveolin-1 leads to delayed development of chronic lymphocytic leukemia in Eμ-TCL1 mouse model.
    Shukla A; Cutucache CE; Sutton GL; Pitner MA; Rai K; Rai S; Opavsky R; Swanson PC; Joshi SS
    Exp Hematol; 2016 Jan; 44(1):30-7.e1. PubMed ID: 26435347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic lymphocytic leukemia disease progression is accelerated by APRIL-TACI interaction in the TCL1 transgenic mouse model.
    Lascano V; Guadagnoli M; Schot JG; Luijks DM; Guikema JE; Cameron K; Hahne M; Pals S; Slinger E; Kipps TJ; van Oers MH; Eldering E; Medema JP; Kater AP
    Blood; 2013 Dec; 122(24):3960-3. PubMed ID: 24100449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PTPROt-mediated regulation of p53/Foxm1 suppresses leukemic phenotype in a CLL mouse model.
    Motiwala T; Kutay H; Zanesi N; Frissora FW; Mo X; Muthusamy N; Jacob ST
    Leukemia; 2015 Jun; 29(6):1350-9. PubMed ID: 25482129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TCL1 shows a regulated expression pattern in chronic lymphocytic leukemia that correlates with molecular subtypes and proliferative state.
    Herling M; Patel KA; Khalili J; Schlette E; Kobayashi R; Medeiros LJ; Jones D
    Leukemia; 2006 Feb; 20(2):280-5. PubMed ID: 16341048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic lymphocytic leukemia of Emu-TCL1 transgenic mice undergoes rapid cell turnover that can be offset by extrinsic CD257 to accelerate disease progression.
    Enzler T; Kater AP; Zhang W; Widhopf GF; Chuang HY; Lee J; Avery E; Croce CM; Karin M; Kipps TJ
    Blood; 2009 Nov; 114(20):4469-76. PubMed ID: 19755673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stromal cells modulate TCL1 expression, interacting AP-1 components and TCL1-targeting micro-RNAs in chronic lymphocytic leukemia.
    Sivina M; Hartmann E; Vasyutina E; Boucas JM; Breuer A; Keating MJ; Wierda WG; Rosenwald A; Herling M; Burger JA
    Leukemia; 2012 Aug; 26(8):1812-20. PubMed ID: 22460735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accelerated progression of chronic lymphocytic leukemia in Eμ-TCL1 mice expressing catalytically inactive RAG1.
    Nganga VK; Palmer VL; Naushad H; Kassmeier MD; Anderson DK; Perry GA; Schabla NM; Swanson PC
    Blood; 2013 May; 121(19):3855-66, S1-16. PubMed ID: 23502221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD74 is dispensable for development of chronic lymphocytic leukemia in
    Barthel R; Fedorchenko O; Velmans T; Rosen N; Nguyen PH; Reinart N; Florin A; Herling M; Hallek M; Fingerle-Rowson G
    Leuk Lymphoma; 2020 Dec; 61(12):2799-2810. PubMed ID: 32667245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T Cell Leukemia/Lymphoma 1A is essential for mouse epidermal keratinocytes proliferation promoted by insulin-like growth factor 1.
    Bresin A; Ragone G; Cristofoletti C; Arcelli D; Bassi C; Caprini E; Fiorenza MT; Helmer Citterich M; Russo G; Narducci MG
    PLoS One; 2018; 13(10):e0204775. PubMed ID: 30286151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.